These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22008450)

  • 1. An objective assessment of conformational variability in complexes of hepatitis C virus polymerase with non-nucleoside inhibitors.
    Caillet-Saguy C; Simister PC; Bressanelli S
    J Mol Biol; 2011 Dec; 414(3):370-84. PubMed ID: 22008450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Slow binding inhibition and mechanism of resistance of non-nucleoside polymerase inhibitors of hepatitis C virus.
    Hang JQ; Yang Y; Harris SF; Leveque V; Whittington HJ; Rajyaguru S; Ao-Ieong G; McCown MF; Wong A; Giannetti AM; Le Pogam S; Talamás F; Cammack N; Nájera I; Klumpp K
    J Biol Chem; 2009 Jun; 284(23):15517-29. PubMed ID: 19246450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of substituted N-phenylbenzenesulphonamides as a novel class of non-nucleoside hepatitis C virus polymerase inhibitors.
    May MM; Brohm D; Harrenga A; Marquardt T; Riedl B; Kreuter J; Zimmermann H; Ruebsamen-Schaeff H; Urban A
    Antiviral Res; 2012 Aug; 95(2):182-91. PubMed ID: 22580131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NMR reveals the intrinsically disordered domain 2 of NS5A protein as an allosteric regulator of the hepatitis C virus RNA polymerase NS5B.
    Bessa LM; Launay H; Dujardin M; Cantrelle FX; Lippens G; Landrieu I; Schneider R; Hanoulle X
    J Biol Chem; 2017 Nov; 292(44):18024-18043. PubMed ID: 28912275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors.
    Biswal BK; Cherney MM; Wang M; Chan L; Yannopoulos CG; Bilimoria D; Nicolas O; Bedard J; James MN
    J Biol Chem; 2005 May; 280(18):18202-10. PubMed ID: 15746101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining 3-D quantitative structure-activity relationship with ligand based and structure based alignment procedures for in silico screening of new hepatitis C virus NS5B polymerase inhibitors.
    Musmuca I; Caroli A; Mai A; Kaushik-Basu N; Arora P; Ragno R
    J Chem Inf Model; 2010 Apr; 50(4):662-76. PubMed ID: 20225870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-nucleoside inhibitors binding to hepatitis C virus NS5B polymerase reveal a novel mechanism of inhibition.
    Biswal BK; Wang M; Cherney MM; Chan L; Yannopoulos CG; Bilimoria D; Bedard J; James MN
    J Mol Biol; 2006 Aug; 361(1):33-45. PubMed ID: 16828488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual Allosteric Inhibitors Jointly Modulate Protein Structure and Dynamics in the Hepatitis C Virus Polymerase.
    Brown JA; Thorpe IF
    Biochemistry; 2015 Jul; 54(26):4131-41. PubMed ID: 26066778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ligand-induced changes in hepatitis C virus NS5B polymerase structure.
    Rigat K; Wang Y; Hudyma TW; Ding M; Zheng X; Gentles RG; Beno BR; Gao M; Roberts SB
    Antiviral Res; 2010 Nov; 88(2):197-206. PubMed ID: 20813137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors.
    Di Maio VC; Cento V; Mirabelli C; Artese A; Costa G; Alcaro S; Perno CF; Ceccherini-Silberstein F
    Antimicrob Agents Chemother; 2014 May; 58(5):2781-97. PubMed ID: 24590484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase.
    Kukolj G; McGibbon GA; McKercher G; Marquis M; Lefèbvre S; Thauvette L; Gauthier J; Goulet S; Poupart MA; Beaulieu PL
    J Biol Chem; 2005 Nov; 280(47):39260-7. PubMed ID: 16188890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients.
    Le Pogam S; Seshaadri A; Kosaka A; Chiu S; Kang H; Hu S; Rajyaguru S; Symons J; Cammack N; Nájera I
    J Antimicrob Chemother; 2008 Jun; 61(6):1205-16. PubMed ID: 18343801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors.
    Herlihy KJ; Graham JP; Kumpf R; Patick AK; Duggal R; Shi ST
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3523-31. PubMed ID: 18694956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for hepatitis C virus non-nucleotide resistance mutations in treatment-naive women.
    Dryer PD; Limketkai BN; Martin CM; Ma G; Sherman KE; Taylor LE; Mayer KH; Jamieson DJ; Blackard JT
    J Antimicrob Chemother; 2009 Nov; 64(5):945-8. PubMed ID: 19767319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural basis for resistance of the genotype 2b hepatitis C virus NS5B polymerase to site A non-nucleoside inhibitors.
    Rydberg EH; Cellucci A; Bartholomew L; Mattu M; Barbato G; Ludmerer SW; Graham DJ; Altamura S; Paonessa G; De Francesco R; Migliaccio G; Carfí A
    J Mol Biol; 2009 Jul; 390(5):1048-59. PubMed ID: 19505479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-Heteroarylimino-5-arylidene-4-thiazolidinones as a new class of non-nucleoside inhibitors of HCV NS5B polymerase.
    Küçükgüzel I; Satılmış G; Gurukumar KR; Basu A; Tatar E; Nichols DB; Talele TT; Kaushik-Basu N
    Eur J Med Chem; 2013 Nov; 69():931-41. PubMed ID: 24161679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple virtual screening approaches for finding new hepatitis C virus RNA-dependent RNA polymerase inhibitors: structure-based screens and molecular dynamics for the pursue of new poly pharmacological inhibitors.
    Elhefnawi M; ElGamacy M; Fares M
    BMC Bioinformatics; 2012; 13 Suppl 17(Suppl 17):S5. PubMed ID: 23282180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural insights into NS5B protein of novel equine hepaciviruses and pegiviruses complexed with polymerase inhibitors.
    de Albuquerque PPLF; Santos LHS; Antunes D; Caffarena ER; Figueiredo AS
    Virus Res; 2020 Mar; 278():197867. PubMed ID: 31972246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a novel series of non-nucleoside thumb pocket 2 HCV NS5B polymerase inhibitors.
    Stammers TA; Coulombe R; Rancourt J; Thavonekham B; Fazal G; Goulet S; Jakalian A; Wernic D; Tsantrizos Y; Poupart MA; Bös M; McKercher G; Thauvette L; Kukolj G; Beaulieu PL
    Bioorg Med Chem Lett; 2013 May; 23(9):2585-9. PubMed ID: 23545108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of potent and broad genotypically active NS5B HCV non-nucleoside inhibitors binding to the thumb domain allosteric site 2 of the viral polymerase.
    Pierra Rouvière C; Amador A; Badaroux E; Convard T; Da Costa D; Dukhan D; Griffe L; Griffon JF; LaColla M; Leroy F; Liuzzi M; Loi AG; McCarville J; Mascia V; Milhau J; Onidi L; Paparin JL; Rahali R; Sais E; Seifer M; Surleraux D; Standring D; Dousson C
    Bioorg Med Chem Lett; 2016 Sep; 26(18):4536-4541. PubMed ID: 27520942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.